inReview Continuing Professional Development, Schulich School of Medicine & Dentistry, The University of Western Ontario

Fine-Tuning Pharmacotherapy in Psychiatry

Programme Description & Educational Objectives

In this activity, two Canadian physicians discuss optimal strategies for switching antipsychotic therapy in patients with schizophrenia or bipolar disorder, addressing when and how to transition between therapies, as well as ways to minimise the potential for side effects by looking at the different pharmacologic properties of the available therapies.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of Canadian psychiatrists.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Certificates of Completion are awarded upon successful completion of the post-test and evaluation form.

Media:
Internet
Release and Expiration Dates:
April 11, 2011 - April 10, 2012
Time to Complete:
30 minutes
Faculty & Disclosure / Conflict of Interest Policy

Continuing Professional Development, Schulich School of Medicine & Dentistry, The University of Western Ontario has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Planning Committee

Course Director
Simon S. Chiu, MD, PhD, FRCP(C), ABPN
Associate Professor, Department of Psychiatry
University of Western Ontario
London, Ontario

Simon S. Chiu, MD, PhD, FRCP(C), ABPN, currently has no financial interests/relationships or affiliations in relation to this activity.


Abraham Rudnick, BMedSc, MD, MPsych, PhD, CPRP, FRCPC
Associate Professor, Departments of Psychiatry and Philosophy
University of Western Ontario
London, Ontario

Abraham Rudnick, BMedSc, MD, MPsych, PhD, CPRP, FRCPC, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca Pharmaceuticals LP; Janssen Inc.; Lilly Research Laboratories; Mylan Laboratories Inc.; and Novartis Pharmaceuticals Canada Inc.


Iouri Rybak, MD, FRCPC
Assistant Professor, Department of Psychiatry
University of Western Ontario
London, Ontario

Iouri Rybak, MD, FRCPC, currently has no financial interests/relationships or affiliations in relation to this activity.


Interviewees

Diane McIntosh, BSc Pharmacy, MD, FRCPC
Department of Psychiatry
University of British Columbia
Vancouver, British Columbia

Diane McIntosh, BSc Pharmacy, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Pharmaceuticals LP; Biovail Corporation; Bristol-Myers Squibb Canada Co.; Eli Lilly and Company; Janssen Inc.; Lundbeck Canada; Shire Canada Inc.; and Pfizer Canada Inc.
Grant/Research Support from AstraZeneca Pharmaceuticals LP.
Honoraria from AstraZeneca Pharmaceuticals LP; Biovail Corporation; Bristol-Myers Squibb Canada Co.; Eli Lilly and Company; Janssen Inc.; Lundbeck Canada; Shire Canada Inc.; and Pfizer Canada Inc.


David Bloom, MD, FRCPC
Intellectual Handicap
with Psychiatric Comorbidity Program
Psychotic Disorders Program
Department of Psychiatry
McGill University
Montréal, Québec

David Bloom, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Pharmaceuticals LP; Biovail Corporation; Eli Lilly and Company; Janssen Inc.; Novartis Pharmaceuticals Canada Inc.; and Pfizer Canada Inc.
Honoraria from AstraZeneca Pharmaceuticals LP; Biovail Corporation; Eli Lilly and Company; Janssen Inc.; Novartis Pharmaceuticals Canada Inc.; and Pfizer Canada Inc.


Accreditation

University of Western Ontario
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and co-developed by Continuing Professional Development, Schulich School of Medicine & Dentistry, The University of Western Ontario. (0.5 hr)

Support

This activity is supported by an educational grant from Pfizer Canada Inc.

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

All contents copyright © 2000-, PeerView Press. All rights reserved.